Genetic variation in the DNA repair genes is predictive of outcome in lung cancer

Human Molecular Genetics

Volumn 16, Issue 19, 2007, Pages 2333-2340

  Matakidou, Athena ^a   El Galta, Rachid ^a   Webb, Emily L ^a   Rudd, Matthew F ^a   Bridle, Helen ^b   Eisen, Tim ^b   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; PLATINUM COMPLEX;

ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; EXCISION REPAIR; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOSINE TRIPHOSPHATASES; DNA HELICASES; DNA POLYMERASE II; DNA REPAIR; DNA REPAIR ENZYMES; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; ENDONUCLEASES; EXODEOXYRIBONUCLEASES; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 34548724426     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddm190     Document Type: Article

References (31)

1. Jemal, A., Thomas, A., Murray, T. and Thun, M. (2002) Cancer statistics, 2002. CA Cancer J. Clin., 52, 23-47.
2. Hunter, K. (2006) Host genetics influence tumour metastasis. Nat. Rev. Cancer, 6, 141-146.
3. Hunter, K.W. and Crawford, N.P. (2006) Germ line polymorphism in metastatic progression. Cancer Res., 66, 1251-1254.
4. Lenz, H.J. (2004) The use and development of germline polymorphisms in clinical oncology. J. Clin. Oncol., 22, 2519-2521.
5. Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J.C., Lynch, T.J., Neuberg, D.S. and Christiani, D.C. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol., 22, 2594-2601.
6. Wang, Y.C., Chen, C.Y., Chen, S.K., Chang, Y.Y. and Lin, P. (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: Association with lung cancer susceptibility and prognosis. Clin. Cancer Res., 5, 129-134.
7. Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nunez, L. et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15, 1194-1203.
8. Nakamura, H., Saji, H., Idiris, A., Kawasaki, N., Hosaka, M., Ogata, A., Saijo, T. and Kato, H. (2003) Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin. Cancer Res., 9, 2294-2299.
9. Rosell, R., Pifarre, A., Monzo, M., Astudillo, J., Lopez-Cabrerizo, M.P., Calvo, R., Moreno, I., Sanchez-Cespedes, M., Font, A. and Navas-Palacios, J.J. (1997) Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int. J. Cancer, 74, 330-334.
10. Johnson, S., Stephenson, J. and O'Dwyer, P. (2001) Cisplatin and its Analogues, 6th edn. Lippincott Williams and Wilkins, Philadelphia.
11. Bosken, C.H., Wei, Q., Amos, C.I. and Spitz, M.R. (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl. Cancer Inst., 94, 1091-1099.
12. Jordan, P. and Carmo-Fonseca, M. (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol. Life Sci., 57, 1229-1235.
13. Shellard, S.A., Fichtinger-Schepman, A.M., Lazo, J.S. and Hill, B.T. (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs, 4, 491-500.
14. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447, 661-678.
15. Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D.S., Wain, J.C., Lynch, T.J., Su, L. and Christiani, D.C. (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res., 10, 4939-4943.
16. Ryu, J.S., Hong, Y.C., Han, H.S., Lee, J.E., Kim, S., Park, Y.M., Kim, Y.C. and Hwang, T.S. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 44, 311-316.
17. Yoon, S.M., Hong, Y.C., Park, H.J., Lee, J.E., Kim, S.Y., Kim, J.H., Lee, S.W., Park, S.Y., Lee, J.S. and Choi, E.K. (2005) The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 63, 885-891.
18. Wu, X., Gu, J., Wu, T.T., Swisher, S.G., Liao, Z., Correa, A.M., Liu, J., Etzel, C.J., Amos, C.I., Huang, M. et al. (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J. Clin. Oncol., 24, 3789-3798.
19. Takemiya, M., Shiraishi, S., Teramoto, T. and Miki, Y. (1987) Bloom's syndrome with porokeratosis of Mibelli and multiple cancers of the skin, lung and colon. Clin. Genet., 31, 35-44.
20. Yamanaka, A., Hirai, T., Ohtake, Y. and Kitagawa, M. (1997) Lung cancer associated with Werner's syndrome: A case report and review of the literature. Jpn. J. Clin. Oncol., 27, 415-418.
21. Chaney, S.G. and Vaisman, A. (1999) Specificity of platinum-DNA adduct repair. J Inorg. Biochem., 77, 71-81.
22. Chirnomas, D., Taniguchi, T., de la Vega, M., Vaidya, A.P., Vasserman, M., Hartman, A.R., Kennedy, R., Foster, R., Mahoney, J., Seiden, M.V. et al. (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther., 5, 952-961.
23. Vodicka, P., Kumar, R., Stetina, R., Sanyal, S., Soucek, P., Haufroid, V., Dusinska, M., Kuricova, M., Zamecnikova, M., Musak, L. et al. (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis, 25, 757-763.
24. Xi, T., Jones, I.M. and Mohrenweiser, H.W. (2004) Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics, 83, 970-979.
25. Perneger, T.V. (1998) What's wrong with Bonferroni adjustments. Bmj 316, 1236-1238.
26. Matakidou, A., Eisen, T., Bridle, H., O'Brien, M., Mutch, R. and Houlston, R.S. (2005) Case-control study of familial lung cancer risks in UK women. Int. J. Cancer, 116, 445-450.
27. Rudd, M.F., Williams, R.D., Webb, E.L., Schmidt, S., Sellick, G.S. and Houlston, R.S. (2005) The predicted impact of coding single nucleotide polymorphisms database. Cancer Epidemiol. Biomarkers Prev., 14 2598-2604.
28. Ng, P.C. and Henikoff, S. (2002) Accounting for human polymorphisms predicted to affect protein function. Genome Res., 12, 436-446.
29. Klein, J. and Moeschberger, M. (1997) Survival Analysis: Techniques for Censored and Truncated Data, 1st edn.Springer, Berlin.
30. Stephens, M., Smith, N.J. and Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68, 978-989.
31. Farrington, C.P. and Manning, G. (1990) Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat. Med., 9, 1447-1454.